$29.35
0[0.00%]
At close: Apr 22
$29.35
0[0.00%]
PreMarket: 4:00PM EDT
Harmony Biosciences
(NASDAQ:HRMY)Latest News for Harmony Biosciences Stock (NASDAQ:HRMY)
Harmony Biosciences Stock (NASDAQ: HRMY)
Categories: All
Friday, April 12, 2024
Thursday, April 11, 2024
- Needham Reiterates Buy on Harmony Biosciences, Maintains $50 Price TargetBenzinga Newsdesk - Apr 11, 2024, 1:24PM
- Harmony Biosciences shares are trading higher after the company announced exclusive licensing agreement with Bioprojet for TPM-1116 for treatment of narcolepsy.Benzinga Newsdesk - Apr 11, 2024, 8:54AM
- Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize TPM-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist; Harmony Will Pay Bioprojet An Upfront License Fee Of $25.5M For The Exclusive RightBenzinga Newsdesk - Apr 11, 2024, 8:07AM
Tuesday, April 09, 2024
Thursday, March 28, 2024
Tuesday, March 19, 2024
Tuesday, February 27, 2024
Friday, February 23, 2024
Thursday, February 22, 2024
- Analyst Ratings For Harmony BiosciencesBenzinga Insights - Feb 22, 2024, 11:00AM
- Needham Reiterates Buy on Harmony Biosciences, Maintains $53 Price TargetBenzinga Newsdesk - Feb 22, 2024, 8:47AM
- Harmony Biosciences Q4 2023 Adj EPS $0.73 Beats $0.48 Estimate, Sales $168.41M Miss $169.06M EstimateBenzinga Newsdesk - Feb 22, 2024, 7:40AM
- Earnings Scheduled For February 22, 2024Benzinga Insights - Feb 22, 2024, 5:27AM
Wednesday, February 21, 2024
Tuesday, February 20, 2024
Friday, February 16, 2024
Tuesday, January 09, 2024
Monday, January 08, 2024
- Harmony Biosciences Sees 2024 Net Product Revenue Projected Between $700M-$720M; $50M Common Stock Repurchase In Q4 Bringing 2023 Total To $100M; Expect To Continue Opportunistic Share Repurchases In 2024Benzinga Newsdesk - Jan 8, 2024, 8:34AM
- Harmony Biosciences Holdings Sees WAKIX Preliminary Net Revenue Of ~$168M In Q4 And ~$582M In FY23, Up ~31% And ~33% RespectivelyBenzinga Newsdesk - Jan 8, 2024, 8:13AM
Tuesday, January 02, 2024
Thursday, December 07, 2023
Tuesday, December 05, 2023
Friday, November 17, 2023
Wednesday, November 01, 2023
Tuesday, October 31, 2023
- Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Oct 31, 2023, 1:36PM
- Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On TuesdayLisa Levin - Oct 31, 2023, 12:04PM
- Harmony Biosciences Q3 2023 EPS $0.97 May Not Compare To $0.65 Estimate, Revenue $160.268M May Not Compare To $148.608M EstimateBenzinga Newsdesk - Oct 31, 2023, 8:16AM
- Earnings Scheduled For October 31, 2023Benzinga Insights - Oct 31, 2023, 5:44AM
Monday, October 30, 2023
Monday, October 16, 2023
- Why Harmony Biosciences Stock Is Trading Higher TodayRyan Gustafson - Oct 16, 2023, 3:41PM
- Harmony Biosciences shares are trading higher as the stock rebounds after falling Friday on Phase 3 INTUNE study data.Benzinga Newsdesk - Oct 16, 2023, 2:05PM
- Piper Sandler Maintains Overweight on Harmony Biosciences, Lowers Price Target to $42Benzinga Newsdesk - Oct 16, 2023, 1:27PM
- Analyst Ratings for Harmony BiosciencesBenzinga Insights - Oct 16, 2023, 8:00AM
- Needham Maintains Buy on Harmony Biosciences, Lowers Price Target to $53Benzinga Newsdesk - Oct 16, 2023, 6:04AM
- Raymond James Maintains Outperform on Harmony Biosciences, Lowers Price Target to $26Benzinga Newsdesk - Oct 16, 2023, 4:21AM
Friday, October 13, 2023
- Nasdaq Down Over 1%; Wells Fargo Beats ExpectationsLisa Levin - Oct 13, 2023, 2:50PM
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga Insights - Oct 13, 2023, 1:31PM
- Why Belden Shares Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Friday's Mid-Day SessionLisa Levin - Oct 13, 2023, 1:14PM
- Crude Oil Rises Sharply; Citigroup Posts Upbeat EarningsLisa Levin - Oct 13, 2023, 12:01PM
- Why Is Sleep Disorder Related Harmony Biosciences Stock Trading Lower Today?Vandana Singh - Oct 13, 2023, 10:22AM
- Harmony Biosciences shares are trading lower after the company reported topline data from its Phase 3 INTUNE study of pitolisant for IH, noting no statistically significant difference was observed between pitolisant and placebo on ESS.Benzinga Newsdesk - Oct 13, 2023, 8:10AM
- Harmony Biosciences' Releases Topline Results From INTUNE Phase 3 Study Of Pitolisant For Idiopathic Hypersomnia; No Statistically Significant Difference Was Observed Between Pitolisant And Placebo Groups On Epworth Sleepiness Scale, The Primary EndpointBenzinga Newsdesk - Oct 13, 2023, 8:05AM